Latanoprost Versus Fotil

To compare the intraocular pressure effect and safety of latanoprost 0.005% given every evening versus PTFC given twice daily.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Open-angle Glaucoma Eye Diseases Glaucoma Glaucoma, Open-Angle Ocular Hypertension

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Gabinety Okulistyczne, Bydgoszcz, Poland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

adults with primary open-angle or pigment dispersion glaucoma, or ocular hypertension
untreated intraocular pressure should be between 24-36 mm Hg inclusive
visual acuity should be 5/50 or better in both eyes

Exclusion criteria

presence of exfoliation syndrome or exfoliation glaucoma
contraindications to study medications
any anticipated change in systemic hypotensive therapy

Treatment and study plan

Latanoprost 0.005%

Drug

Fotil

Drug

Placebo

Drug

Sponsors and collaborators

Lead sponsor

Pharmaceutical Research Network

Other

Registry information

Important dates

Study start: 2005
Study completion: 2007
First posted: Mar 20, 2006
Registry last updated: Oct 24, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed